GRAIL (NASDAQ:GRAL) Issues Earnings Results, Beats Expectations By $0.47 EPS

05 May 2026, 21:14 by Renee Jackson · The Cerbat Gem

GRAIL (NASDAQ:GRAL – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($2.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.76) by $0.47, Zacks reports. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.11%.

Here are the key takeaways from GRAIL’s conference call:

GRAIL sold over 56,000 Galleri tests in Q1 (a 50% YoY increase) and reported screening revenue of $39.8M, citing expanding physician adoption and new health-system and employer partnerships.
The FDA has accepted GRAIL’s PMA submission for review (PATHFINDER 2 and NHS-Galleri data plus a bridging analysis), but timing, the possibility of an advisory committee, and the ultimate outcome remain uncertain.
The NHS-Galleri trial did not meet its combined primary endpoint (no significant reduction in combined stage 3+4), which could be viewed unfavorably by some stakeholders despite accompanying secondary benefits.
Q1 non-GAAP results improved with adjusted gross profit of $19.7M, a narrower adjusted EBITDA loss (-$79.9M), a 12% smaller net loss, and cash of $823.1M to fund growth and milestones.
Management reiterated 2026 revenue guidance (22–32%), plans a mid-year salesforce ramp and Epic/Quest/Athena integrations to ease provider ordering, but the pace of uptake from new digital and employer partners and ASP/mix effects are uncertain.

GRAIL Trading Down 2.3%

GRAIL stock traded down $1.26 during mid-day trading on Tuesday, hitting $54.40. The company had a trading volume of 720,165 shares, compared to its average volume of 699,775. GRAIL has a 12-month low of $29.95 and a 12-month high of $118.84. The company’s fifty day moving average is $50.40 and its 200-day moving average is $78.71.

Wall Street Analysts Forecast Growth

GRAL has been the subject of a number of research reports. Mizuho assumed coverage on shares of GRAIL in a research note on Friday, April 10th. They issued a “neutral” rating and a $58.00 price objective for the company. Canaccord Genuity Group decreased their price target on shares of GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Piper Sandler assumed coverage on shares of GRAIL in a research report on Friday, April 10th. They set a “neutral” rating and a $54.00 price target for the company. Robert W. Baird set a $82.00 price target on shares of GRAIL in a research report on Friday, February 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a research report on Tuesday, April 21st. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $68.63.

Read Our Latest Stock Analysis on GRAL

Insider Transactions at GRAIL

In other news, President Joshua J. Ofman sold 61,665 shares of the firm’s stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $3,078,316.80. Following the sale, the president owned 371,216 shares of the company’s stock, valued at $18,531,102.72. This trade represents a 14.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Aaron Freidin sold 45,806 shares of the firm’s stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the sale, the chief financial officer directly owned 260,669 shares in the company, valued at $13,012,596.48. The trade was a 14.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 310,267 shares of company stock valued at $15,485,396 in the last 90 days.

Institutional Investors Weigh In On GRAIL

A number of hedge funds and other institutional investors have recently made changes to their positions in GRAL. Royal Bank of Canada grew its stake in shares of GRAIL by 17.7% during the 1st quarter. Royal Bank of Canada now owns 88,082 shares of the company’s stock worth $2,250,000 after purchasing an additional 13,264 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of GRAIL by 28.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock worth $76,000 after purchasing an additional 623 shares during the period. NewEdge Advisors LLC lifted its position in shares of GRAIL by 390.3% during the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock valued at $45,000 after buying an additional 1,401 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of GRAIL by 37.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 92,465 shares of the company’s stock valued at $2,362,000 after buying an additional 25,177 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of GRAIL by 115.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 79,544 shares of the company’s stock valued at $4,090,000 after buying an additional 42,675 shares in the last quarter.

About GRAIL

(Get Free Report)

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.